---
title: Accelerating Rare Disease Drug Development with Wearable DHTs
description: In this webinar, panelists discuss DHTs in rare disease trials, including a case study on digital measures as a pivotal trial's primary endpoint.
image: https://landing.ametris.com/hubfs/AG_Marketing_Webinars_RareDisease_Social_On-Demand_FINAL.jpg
---

[![ActiGraph](https://landing.ametris.com/hs-fs/hubfs/ActiGraph-Logo-Reversed.png?width=3030&height=618&name=ActiGraph-Logo-Reversed.png "ActiGraph")](https://theactigraph.com/?hsLang=en)

## On-Demand Webinar

# Accelerating Rare Disease Drug Development with Wearable Digital Health Technologies

[ WATCH NOW ](https://landing.theactigraph.com/rare-disease-webinar-on-demand-gate?hsLang=en#watch-now)

## Overview

More than 90% of rare diseases do not have any treatment, representing a substantial unmet need for patients. The development of new therapies is especially challenging given the poor understanding of rare diseases in general and the lack of established endpoints for clinical trials.

Sensor-based digital health technologies (DHTs), such as low-burden wearable devices, offer new opportunities to advance rare disease research by providing patient-centric, objective measures on how patients function in the real world.

During this 60-minute webinar, experts from [ActiGraph](https://theactigraph.com/?hsLang=en), [Bellerophon Therapeutics](https://bellerophon.com/), and [IQVIA](https://www.iqvia.com/) discuss these challenges and opportunities, including a case study on how digital measures of physical activity are being used as a primary endpoint in a pivotal trial, enabling the reduction of the sample size by a factor of two.

## Learning Objectives

- Identify unmet needs and challenges of developing treatment for rare disease
- Discover opportunities for wearable and sensor-based DHTs
- Hear a case study about how Bellerophon Therapeutics is using digital measures of physical activity as a primary endpoint in a pivotal trial

## Speakers

[![Christine Guo, PhD](https://landing.ametris.com/hubfs/AG_Marketing_Webinars_RareDisease_Headshots_ChristineGuo_FINAL-1.png "Christine Guo, PhD")](https://www.linkedin.com/in/congguo/)

Christine Guo, PhD

###### Chief Scientific Officer

###### *ActiGraph*

[![Sylvain Zorman, PhD](https://landing.ametris.com/hubfs/AG_Marketing_Webinars_RareDisease_Headshots_SylvainZorman_FINAL-1.png "Sylvain Zorman, PhD")](https://www.linkedin.com/in/sylvain-zorman/)

Sylvain Zorman, PhD

Director of Digital Health Science

*ActiGraph*

[![Peter Fernandes](https://landing.ametris.com/hubfs/AG_Marketing_Webinars_RareDisease_Headshots_PeterFernandes_FINAL-1.png "Peter Fernandes")](https://www.linkedin.com/in/peter-fernandes-b2b11510/)

Peter Fernandes

Chief Executive Officer

*Bellerophon **Therapeutics*

[![Salma Ajraoui, PhD](https://landing.ametris.com/hubfs/AG_Marketing_Webinars_RareDisease_Headshots_SalmaAjraoui_FINAL-1.png "Salma Ajraoui, PhD")](https://www.linkedin.com/in/salma-a-90a46135/)

Salma Ajraoui, PhD

Digital Practice Lead, Patient Centered Solutions

*IQVIA*

---

## Watch the On-Demand Webinar

![](https://px.ads.linkedin.com/collect/?pid=196258&fmt=gif)